Dr. Sattva Neelapu – MD Anderson Cancer Center (Houston, TX)
Dr. Sattva Neelapu – MD Anderson Cancer Center
Dr. Sattva S Neelapu is a tenured Professor, Deputy Chair ad interim, and Director of Translational Research in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. After graduating from medical school at the Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India, he moved to the United States for Internal Medicine residency at the Coney Island Hospital in Brooklyn, New York, where he also served as a Chief Medical Resident. He completed his clinical fellowship in Medical Oncology and postdoctoral fellowship in tumor immunology and immunotherapy at the National Cancer Institute, National Institutes of Health, Bethesda, Maryland. As a physician-scientist at MD Anderson, his research is focused on clinical and translational development of novel immunotherapies for B-cell malignancies. His laboratory characterized some of the major immunosuppressive mechanisms in the tumor microenvironment of B-cell malignancies, identified TCL1 as a novel shared tumor-associated antigen for B-cell lymphomas, and investigated novel targets for CAR T-cell therapy in lymphoma and myeloma. His work on the pivotal trial of axicabtagene ciloleucel CD19 CAR T-cell therapy in aggressive B-cell lymphomas led to its FDA approval as the first CAR T therapy for lymphoma. Dr. Neelapu has authored or co-authored over 150 publications.